Advertisement

Overall- and Disease-Specific Survival in Prostata Cancer: Too Long to Wait?

  • Wolfgang Lilleby
Chapter
Part of the Medical Radiology book series (MEDRAD)

Abstract

There is a substantial body of evidence supporting the efficacy of primary radiotherapy in men with prostate cancer. Unfortuantely, and especially men with prognostic high risk prostate cancer will experience undertreatment with fatal consequences in this population. On the other hand, low risk patients should benefit from diagnostic breakthroughs achieved by modern staging techniques and optimised treatment developments, sparing these men for unnecessary side effects and harms. It is up to the uro-oncologic community to encourage clinical randomised trials comparing radiotherapy with surgery to improve the disease-specific survival and overall outcome in these patients.

Keywords

Overall Survival Gleason Score Androgen Deprivation Therapy Adjuvant Androgen Deprivation Therapy Androgen Deprivation Therapy Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Albertsen PC, Hanley JA, Barrows GH, Penson DF, Kowalczyk PD, Sanders MM, Fine J (2005) Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 97(17):1248–1253PubMedCrossRefGoogle Scholar
  2. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, Gelmann EP, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA et al (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310–1319PubMedCentralPubMedCrossRefGoogle Scholar
  3. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR, Fouad MN, Isaacs C, Kvale PA, Reding DJ, Weissfeld JL, Yokochi LA et al (2012) Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 104(2):125–132PubMedCentralPubMedCrossRefGoogle Scholar
  4. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, Haggman M, Andersson SO, Bratell S, Spangberg A, Palmgren J et al (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364(18):1708–1717PubMedCrossRefGoogle Scholar
  5. Bolla M, de Reijke TM, Van TG, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, Kariakine O, van der Steen-Banasik EM et al (2009) Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 360(24):2516–2527PubMedCrossRefGoogle Scholar
  6. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Gil T, Collette L, Pierart M (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337(5):295–300PubMedCrossRefGoogle Scholar
  7. Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A (2010) Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 46(17):3040–3052PubMedCrossRefGoogle Scholar
  8. Brenner DJ, Hall EJ, Curtis RE, Ron E (2005) Prostate radiotherapy is associated with second cancers in many organs, not just the colorectum. Gastroenterology 129(2):773–774PubMedCrossRefGoogle Scholar
  9. Bria E, Cuppone F, Giannarelli D, Milella M, Ruggeri EM, Sperduti I, Pinnaro P, Terzoli E, Cognetti F, Carlini P (2009) Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer? Meta-analysis of randomized trials. Cancer 115(15):3446–3456PubMedCrossRefGoogle Scholar
  10. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, Bray F (2012) International variation in prostate cancer incidence and mortality rates. Eur Urol 61(6):1079–1092PubMedCrossRefGoogle Scholar
  11. Crook JM, Gomez-Iturriaga A, Wallace K, Ma C, Fung S, Alibhai S, Jewett M, Fleshner N (2011) Comparison of health-related quality of life 5 years after SPIRIT: surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol 29(4):362–368PubMedCrossRefGoogle Scholar
  12. Dall’Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS (2012) Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol 62(6):976–983PubMedCrossRefGoogle Scholar
  13. D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW (2008) Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299(3):289–295PubMedGoogle Scholar
  14. Dearnaley DP, Sydes MR, Graham JD, Aird EG, Bottomley D, Cowan RA, Huddart RA, Jose CC, Matthews JH, Millar J, Moore AR, Morgan RC et al (2007) Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 8(6):475–487PubMedCrossRefGoogle Scholar
  15. Dickinson P, Malik J, Mandall P, Swindell R, Bottomley D, Hoskin P, Logue J, Wylie J (2013) Five year outcomes following I-125 seed brachytherapy for low risk prostate cancer at three United Kingdom cancer centres. BJU Int. doi: 10.1111/bju.12358Google Scholar
  16. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de KH (2009) Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 101(6):374–383Google Scholar
  17. Eccles BK, Cross W, Rosario DJ, Doble A, Parker C, Logue J, Little L, Stanton L, Bottomley D (2013) SABRE 1 (Surgery Against Brachytherapy—a Randomised Evaluation): feasibility randomised controlled trial (RCT) of brachytherapy vs radical prostatectomy in low-intermediate risk clinically localised prostate cancer. BJU Int 112(3):330–337PubMedCrossRefGoogle Scholar
  18. Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, Feng Z, Wood DP, Eastham JA, Yossepowitch O, Rabah DM, Kattan MW et al (2011) Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 185(3):869–875PubMedCentralPubMedCrossRefGoogle Scholar
  19. Epstein JI, Feng Z, Trock BJ, Pierorazio PM (2012) Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 61(5):1019–1024PubMedCrossRefGoogle Scholar
  20. Fleming TR, DeMets DL (1996) Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125(7):605–613PubMedCrossRefGoogle Scholar
  21. Giberti C, Chiono L, Gallo F, Schenone M, Gastaldi E (2009) Radical retropubic prostatectomy versus brachytherapy for low-risk prostatic cancer: a prospective study. World J Urol 27(5):607–612PubMedCrossRefGoogle Scholar
  22. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU (2003) Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the radiation therapy oncology group protocol 92–02. J Clin Oncol 21(21):3972–3978PubMedCrossRefGoogle Scholar
  23. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N (2011) Schmid HP, van der KT, Wiegel T, Zattoni F. [EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease]. Actas Urol Esp 35(9):501–514PubMedGoogle Scholar
  24. Hinnen KA, Battermann JJ, van Roermund JG, Moerland MA, Jurgenliemk-Schulz IM, Frank SJ, van VM (2010) Long-term biochemical and survival outcome of 921 patients treated with I-125 permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 76(5):1433–1438Google Scholar
  25. Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L (2012) Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol 103(2):217–222PubMedCrossRefGoogle Scholar
  26. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90PubMedCrossRefGoogle Scholar
  27. Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA (2012) Prostate cancer-specific mortality after definitive radiation therapy: who dies of disease? Eur J Cancer 48(11):1664–1671Google Scholar
  28. Kovacs G, Potter R, Loch T, Hammer J, Kolkman-Deurloo IK, de la Rosette JJ, Bertermann H (2005) GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer. Radiother Oncol 74(2):137–148PubMedCrossRefGoogle Scholar
  29. Kuban DA, Dong L (2004) High-dose intensity modulated radiation therapy for prostate cancer. Curr Urol Rep 5(3):197–202PubMedCrossRefGoogle Scholar
  30. Kvale R, Moller B, Angelsen A, Dahl O, Fossa SD, Halvorsen OJ, Hoem L, Solberg A, Wahlqvist R, Bray F (2010) Regional trends in prostate cancer incidence, treatment with curative intent and mortality in Norway 1980–2007. Cancer Epidemiol 34(4):359–367PubMedCrossRefGoogle Scholar
  31. Kyrdalen AE, Dahl AA, Hernes E, Hem E, Fossa SD (2010) Fatigue in prostate cancer survivors treated with definitive radiotherapy and LHRH analogs. Prostate 70(13):1480–1489PubMedCrossRefGoogle Scholar
  32. Lawton CA, DeSilvio M, Roach M III, Uhl V, Kirsch R, Seider M, Rotman M, Jones C, Asbell S, Valicenti R, Hahn S, Thomas CR Jr (2007) An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94–13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69(3):646–655PubMedCentralPubMedCrossRefGoogle Scholar
  33. Lilleby W, Stensvold A, Dahl AA (2013) Intensity-modulated radiotherapy to the pelvis and androgen deprivation in men with locally advanced prostate cancer: a study of adverse effects and their relation to quality of life. Prostate 73(10):1038–1047PubMedCrossRefGoogle Scholar
  34. Lilleby W, Tafjord G, Raabe NK (2012) Implementation of high-dose-rate brachytherapy and androgen deprivation in patients with prostate cancer. Int J Radiat Oncol Biol Phys 83(3):933–939PubMedCrossRefGoogle Scholar
  35. Martinez A, Gonzalez J, Spencer W, Gustafson G, Kestin L, Kearney D, Vicini FA (2003) Conformal high dose rate brachytherapy improves biochemical control and cause specific survival in patients with prostate cancer and poor prognostic factors. J Urol 169(3):974–979PubMedCrossRefGoogle Scholar
  36. Morris WJ, Keyes M, Spadinger I, Kwan W, Liu M, McKenzie M, Pai H, Pickles T, Tyldesley S (2013) Population-based 10-year oncologic outcomes after low-dose-rate brachytherapy for low-risk and intermediate-risk prostate cancer. Cancer 119(8):1537–1546PubMedCrossRefGoogle Scholar
  37. Parker C, Muston D, Melia J, Moss S, Dearnaley D (2006) A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 94(10):1361–1368PubMedCentralPubMedCrossRefGoogle Scholar
  38. Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart MF, Bonfrer JM, Incrocci L, Lebesque JV (2006) Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24(13):1990–1996PubMedCrossRefGoogle Scholar
  39. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D (2001) Phase III radiation therapy oncology group (RTOG) trial 86–10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50(5):1243–1252PubMedCrossRefGoogle Scholar
  40. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D (2005) Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma–long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61(5):1285–1290PubMedCrossRefGoogle Scholar
  41. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281(17):1591–1597PubMedCrossRefGoogle Scholar
  42. Prentice RL (2009) Surrogate and mediating endpoints: current status and future directions. J Natl Cancer Inst 101(4):216–217PubMedCrossRefGoogle Scholar
  43. Ray ME, Bae K, Hussain MH, Hanks GE, Shipley WU, Sandler HM (2009) Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial. J Natl Cancer Inst 101(4):228–236PubMedCentralPubMedCrossRefGoogle Scholar
  44. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E et al (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358(12):1250–1261PubMedCrossRefGoogle Scholar
  45. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F et al (2012) Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366(11):981–990PubMedCrossRefGoogle Scholar
  46. Shelley MD, Kumar S, Coles B, Wilt T, Staffurth J, Mason MD (2009) Adjuvant hormone therapy for localised and locally advanced prostate carcinoma: a systematic review and meta-analysis of randomised trials. Cancer Treat Rev 35(7):540–546PubMedCrossRefGoogle Scholar
  47. Solberg A, Haugen OA, Viset T, Bergh A, Tasdemir I, Ahlgren G, Widmark A, Angelsen A (2011) Residual prostate cancer in patients treated with endocrine therapy with or without radical radiotherapy: a side study of the SPCG-7 randomized trial. Int J Radiat Oncol Biol Phys 80(1):55–61PubMedCrossRefGoogle Scholar
  48. Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM (1999) Biological determinants of cancer progression in men with prostate cancer. JAMA 281(15):1395–1400PubMedCrossRefGoogle Scholar
  49. Steinsvik EA, Fossa SD, Axcrona K, Fransson P, Widmark A, Dahl AA (2010) Do perceptions of adverse events differ between patients and physicians? Findings from a randomized, controlled trial of radical treatment for prostate cancer. J Urol 184(2):525–531PubMedCrossRefGoogle Scholar
  50. Stensvold A, Dahl AA, Brennhovd B, Cvancarova M, Fossa SD, Lilleby W, Axcrona K, Smeland S (2012) Methods for prospective studies of adverse effects as applied to prostate cancer patients treated with surgery or radiotherapy without hormones. Prostate 72(6):668–676PubMedCrossRefGoogle Scholar
  51. Stephenson AJ, Bolla M, Briganti A, Cozzarini C, Moul JW, Roach M III, van Poppel H, Zietman A (2012) Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol 61(3):443–451Google Scholar
  52. Valicenti R, Lu J, Pilepich M, Asbell S, Grignon D (2000) Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the radiation therapy oncology group trials. J Clin Oncol 18(14):2740–2746PubMedGoogle Scholar
  53. Viani GA, Stefano EJ, Afonso SL (2009) Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 74(5):1405–1418PubMedCrossRefGoogle Scholar
  54. Wallace K, Fleshner N, Jewett M, Basiuk J, Crook J (2006) Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol 24(25):4158–4162PubMedCrossRefGoogle Scholar
  55. Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, Gospodarowicz M, Sanders K, Kostashuk E, Swanson G, Barber J, Hiltz A et al (2011) Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 378(9809):2104–2111PubMedCentralPubMedCrossRefGoogle Scholar
  56. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, Fossa SD (2009) Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 373(9660):301–308PubMedCrossRefGoogle Scholar
  57. Yoshioka Y (2009) Current status and perspectives of brachytherapy for prostate cancer. Int J Clin Oncol 14(1):31–36PubMedCrossRefGoogle Scholar
  58. Zelefsky MJ, Pei X, Chou JF, Schechter M, Kollmeier M, Cox B, Yamada Y, Fidaleo A, Sperling D, Happersett L, Zhang Z (2011) Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes. Eur Urol 60(6):1133–1139PubMedCrossRefGoogle Scholar
  59. Zelefsky MJ, Yamada Y, Fuks Z, Zhang Z, Hunt M, Cahlon O, Park J, Shippy A (2008) Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 71(4):1028–1033PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.MD Anderson, Norwegian Cancer Consortium—NCC, OncologyOsloNorway

Personalised recommendations